SCYNEXIS, Inc.

NasdaqCM:SCYX 株式レポート

時価総額：US$58.1m

SCYNEXIS 過去の業績

過去 基準チェック /06

SCYNEXISは19.1%の年平均成長率で業績を伸ばしているが、Pharmaceuticals業界はgrowingで9.7%毎年増加している。売上は成長しており、年平均5.1%の割合である。

主要情報

19.06%

収益成長率

37.48%

EPS成長率

Pharmaceuticals 業界の成長5.95%
収益成長率5.13%
株主資本利益率-59.35%
ネット・マージン-120.51%
前回の決算情報31 Mar 2026

最近の業績更新

Recent updates

分析記事 • Jan 23

Companies Like SCYNEXIS (NASDAQ:SCYX) Could Be Quite Risky

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
分析記事 • Sep 09

Can SCYNEXIS (NASDAQ:SCYX) Afford To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
分析記事 • May 17

Here's Why SCYNEXIS (NASDAQ:SCYX) Must Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
分析記事 • Aug 08

Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
分析記事 • Jun 19

Lacklustre Performance Is Driving SCYNEXIS, Inc.'s (NASDAQ:SCYX) 32% Price Drop

The SCYNEXIS, Inc. ( NASDAQ:SCYX ) share price has softened a substantial 32% over the previous 30 days, handing back...
分析記事 • May 12

SCYNEXIS, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

It's been a good week for SCYNEXIS, Inc. ( NASDAQ:SCYX ) shareholders, because the company has just released its latest...
分析記事 • Apr 04

SCYNEXIS (NASDAQ:SCYX) Seems To Use Debt Rather Sparingly

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Seeking Alpha • Apr 02

Scynexis: Update Following Restructuring Of GSK Deal

Summary Scynexis stock price has resumed the downtrend following a restructuring of the GSK deal associated with considerable reduction of pending milestones. SCYX ended 2023 with $98M, but is still trading at a $54M market cap. Cash runway is beyond 2 years, not accounting for pending milestones. Just the milestones from delivery of readouts to GSK and resumption and progress of MARIO trial are expected to cover all 2024 operating expenses. SCYX stock is undervalued in the short/medium term, but its long-term success is unclear considering emerging competition and pipeline limited to SCY-247. Read the full article on Seeking Alpha
分析記事 • Feb 01

Lacklustre Performance Is Driving SCYNEXIS, Inc.'s (NASDAQ:SCYX) Low P/S

With a price-to-sales (or "P/S") ratio of 0.6x SCYNEXIS, Inc. ( NASDAQ:SCYX ) may be sending very bullish signals at...
分析記事 • Dec 21

Does SCYNEXIS (NASDAQ:SCYX) Have A Healthy Balance Sheet?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
分析記事 • Sep 26

Little Excitement Around SCYNEXIS, Inc.'s (NASDAQ:SCYX) Revenues As Shares Take 28% Pounding

SCYNEXIS, Inc. ( NASDAQ:SCYX ) shares have had a horrible month, losing 28% after a relatively good period beforehand...
分析記事 • Aug 17

Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Seeking Alpha • Aug 26

Scynexis: Uninvestible At This Point, Downgrading To A Sell Rating

Summary SCYX has a commercial antifungal Brexafemme. However, we are neutral on its commercial potential as discussed in our previous article. No big pharma deal materialized, and the company raised USD45M through pre-funded warrant offerings. The drug's true upside is in systemic fungal infection; however, catalysts are expected in 2024-2025 at the earliest making the stock uninvestible at this time. We downgrade SCYX to a sell rating. Background As described in detail in our initiation of coverage, we have established an option size position on SCYX based on a potential big pharma M&A and undoubtedly cheap valuation (negative EV) of the company. However, with the recent messy financing deal (described in detail below) and lack of near-term clinical catalyst, we decided to sell out of the position and downgrade the stock. Our rationale is described below. Catalysts are expected in 2024-2025 the earliest The absence of short-term catalysts makes it un-investible for short-mid-term investors in our view. We think the major value driver of the stock is in the systemic infection space, where the catalysts are expected in 2024-2025 (as shown below). Of note, the company announced that the FDA has accepted SCYX's submission of a supplemental New Drug Application regarding label expansion of BREXAFEMME to include "prevention of recurrent vulvovaginal candidiasis" and the target PDUFA date is Nov 2022. We believe the label extension is fully priced in and any positive news will be a selling opportunity for this ticker. SCYX Homepage Messy pre-funded warrants make SCYX uninvestible in our view SCYNEXIS priced its earlier announced underwritten public offering of 3.33M shares of its common stock, prefunded warrants to purchase 11.67M shares of common stock and warrants to purchase an aggregate of 15M shares of its common stock with gross proceeds expected to be ~$45M. The shares and warrants are being sold at $3.00/share and pre-funded warrants are offered at $2.999/pre-funded warrant and accompanying warrants. Underwriters over-allotment is an additional 2.25M of shares and/or warrants to purchase up to 2.25M shares of common stock. The warrants have a seven-year term and an exercise price of $3.45/share. -Source: Seeking Alpha News April 22 The company has a long history of raising capital through messy warrants which caused the stock to tank even after the approval of Brexafemme in June 2021 (as shown below); we believe the same thing is likely to happen with any positive catalyst making the stock uninvestible. Warrants could be a catastrophe as warrant holders can start exercising their warrants and sell into the market when a stock price move above a certain level and the exercised shares were sold into the market killing the share price. SCYX data by YCharts We believe the likelihood of a potential M&A has dropped considerably at this point.
Seeking Alpha • Aug 12

SCYNEXIS Q2 2022 Earnings Preview

SCYNEXIS (NASDAQ:SCYX) is scheduled to announce Q2 earnings results on Monday, August 15th, before market open. The consensus EPS Estimate is -$0.59 (-168.2% Y/Y) and the consensus Revenue Estimate is $1.64M Over the last 3 months, EPS estimates have seen 2 upward revisions and 0 downward. Revenue estimates have seen 0 upward revisions and 3 downward.
Seeking Alpha • Aug 01

FDA accepts Scynexis' application to expand label for vaginal yeast infections treatment

Scynexis (NASDAQ:SCYX) on Monday said the U.S. Food and Drug Administration (FDA) had accepted the biotech's supplemental new drug application (sNDA) to expand the label of its Brexafemme tablets to include the prevention of recurrent vulvovaginal candidiasis. Vulvovaginal candidiasis (VVC) is a type of yeast infection caused by the fungus candida which affects the vagina and the vulva. The company said the FDA had granted the sNDA submission a priority review and was set to decide on it by Nov. 30, or the so-called Prescription Drug User Fee Act date. Brexafemme is already approved to treat VVC. Recurrent VVC would be its second indication.
Seeking Alpha • Jul 19

SCYNEXIS gains after favorable data for antifungal agent in new indication

SCYNEXIS (NASDAQ:SCYX) added ~8% in the morning hours Tuesday after the commercial-stage pharma company announced promising Phase 3 data for its oral antifungal medication ibrexafungerp in patients with recurrent vulvovaginal candidiasis (RVVC). According to the data from the 24-patient CANDLE sub-study, ibrexafungerp, an FDA-authorized therapy for vulvovaginal candidiasis, has led to clinical benefits in RVVC patients who failed to respond to another antifungal therapy called fluconazole. After one day of ibrexafungerp (300 mg BID) treatment, 71% of RVVC patients (17 of 24) were found to have a significant reduction or elimination of signs and symptoms. Additionally, these results were replicated in a subset of patients who also demonstrated positive fungal cultures post-fluconazole treatment. In this 10-patient subgroup, 80% were found to have a favorable clinical response after one-day ibrexafungerp therapy. In June, SCYNEXIS (SCYX) announced the submission of its marketing application for the label expansion of ibrexafungerp in the prevention of RVVC. The supplemental New Drug Application was backed by data from the pivotal Phase 3 CANDLE, which indicated 65% clinical success for the treatment compared to ~53% for the placebo.
分析記事 • Apr 07

SCYNEXIS, Inc. (NASDAQ:SCYX) Analysts Just Cut Their EPS Forecasts Substantially

Today is shaping up negative for SCYNEXIS, Inc. ( NASDAQ:SCYX ) shareholders, with the analysts delivering a...
Seeking Alpha • Mar 07

SCYNEXIS, Inc.: Speculative Buy, Michael Burry Sold, But I Am Buying

We are initiating Scynexis with a target price of USD 23 per share. SCYX offers an extremely attractive set up with 600% upside and limited downside (10-15%) considering its near cash. SCYX's Brexafemme is clinically de-risked and targets an attractive fungal infection space. Even though we expect muted uptake during 2022, we project 200M-400M peak sales within 5 years. The critical inflection point for the stock will be a business development activity from Big Pharma, not near-term earnings. The company has 100M cash, but has a high cash burn rate of around 50M/year and will likely need to raise 50-100M soon to fund its phase 3 trials. Considering close to cash value EV, we view BD activity as more likely and a public offering.
分析記事 • Feb 13

Some Analysts Just Cut Their SCYNEXIS, Inc. (NASDAQ:SCYX) Estimates

Market forces rained on the parade of SCYNEXIS, Inc. ( NASDAQ:SCYX ) shareholders today, when the analysts downgraded...
分析記事 • Dec 03

Is SCYNEXIS (NASDAQ:SCYX) Using Debt In A Risky Way?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Seeking Alpha • Jul 27

Scynexis: Leading The Yeast Infection Treatment Industry

SCYNEXIS lead drug candidate BREXAFEMME recently got FDA approval for the treatment of Vulvovaginal Candidiasis, commonly known as vaginal yeast infections. BREXAFEMME is the first approved drug in the non-azole class for VVC and also the first approved drug in a novel antifungal class in the past 20+ years. The drug has ten years of market regulatory exclusivity and patent protection until 2035. The company’s financial position is robust, with adequate cash to commercialize BREXAFEMME while continuing its current studies.

収支内訳

SCYNEXIS の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

NasdaqCM:SCYX 収益、費用、利益 ( )USD Millions
日付収益収益G+A経費研究開発費
31 Mar 2620-251529
31 Dec 2521-91422
30 Sep 253-251622
30 Jun 253-201525
31 Mar 253-271524
31 Dec 244-211426
30 Sep 249-361433
30 Jun 2410-351531
31 Mar 241401012031
31 Dec 23140672131
30 Sep 23136723228
30 Jun 23136444528
31 Mar 236-915328
31 Dec 225-636327
30 Sep 224-786227
30 Jun 223-496125
31 Mar 222-345823
31 Dec 2113-335024
30 Sep 2113-464026
30 Jun 2112-452830
31 Mar 2112-531934
31 Dec 200-551537
30 Sep 200-271337
30 Jun 200-361239
31 Mar 200-381139
31 Dec 190-541138
30 Sep 190-371034
30 Jun 190-291029
31 Mar 190-31926
31 Dec 180-12922
30 Sep 180-22820
30 Jun 180-31821
31 Mar 180-24820
31 Dec 170-25818
30 Sep 170-21817
30 Jun 170-24817
31 Mar 170-28719
31 Dec 160-30820
30 Sep 160-35922
30 Jun 160-311121
31 Mar 160-301217
31 Dec 150-281216
30 Sep 151-231213
30 Jun 151-191012

質の高い収益: SCYXは現在利益が出ていません。

利益率の向上: SCYXは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: SCYXは利益を出していないが、過去 5 年間で年間19.1%の割合で損失を削減してきた。

成長の加速: SCYXの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: SCYXは利益が出ていないため、過去 1 年間の収益成長をPharmaceuticals業界 ( -5% ) と比較することは困難です。

株主資本利益率

高いROE: SCYXは現在利益が出ていないため、自己資本利益率 ( -59.35% ) はマイナスです。

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/05/25 06:39
終値2026/05/22 00:00
収益2026/03/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

SCYNEXIS, Inc. 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。9

アナリスト機関
Brian Kemp DolliverBrookline Capital Markets
Corey DavisCanaccord Genuity
Liisa BaykoCitizens JMP Securities, LLC